Establishment of epidemiological cutoff values for clinically relevant Sporothrix species using CLSI-broth microdilution.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dos Santos Amanda R, Bonifaz Alexandro, Bombassaro Amanda, Machado Ana Caroline de Sá, Rodrigues Anderson M, Borman Andrew M, Chakrabarti Arunaloke, Chowdary Anuradha, Rediguieri Bruno, Johnson Elizabeth M, Hagen Ferry, Queiroz-Telles Flavio, Gonzalez Gloria M, Garcia-Effron Guillermo, Dib Ferreira Gremião Isabella, Meis Jacques F, Takahashi Juliana Possato Fernandes, Borba Dos Santos Luana Pereira, Melhem Marcia S C, Cappellano Paola, Sâmia Nogueira Brilhante Raimunda, Pereira Sandro Antonio, Gonçalvez Sarah Santos, Kidd Sarah, Zhang Sean X, Rudramurthy Shivaprakash, Rozental Sonia, Cordoba Susana, De Groot Theun, Liu Wei, Wiederhold Nathan P, Meijer Eelco F J, Lockhart Shawn R, Dufresne Philippe J
Аннотация
Sporotrichosis is a globally distributed subcutaneous mycosis caused mainly by Sporothrix brasiliensis, S. schenckii, and S. globosa. Cat-transmitted sporotrichosis, primarily caused by S. brasiliensis in South America and to a lesser extent by S. schenckii in Southeast Asia, is emerging as a substantial public health concern due to its outbreak potential. Itraconazole is the first-line drug for the treatment of humans and cats, but reduced susceptibility has been reported based on previously proposed epidemiological cut-off values (ECVs). To support resistance surveillance, we aimed to establish the Clinical and Laboratory Standards Institute (CLSI)-endorsed ECVs for these clinically relevant Sporothrix species. A total of 3,504 minimum inhibitory concentration (MIC) values for six antifungal agents (amphotericin B, itraconazole, posaconazole, voriconazole, isavuconazole, and terbinafine) were obtained from 19 international laboratories. Four of seven antifungals met the CLSI M57 guidelines criteria to determine the ECV. Established ECVs for amphotericin B were found to be high, with 8 µg/mL for S. brasiliensis and S. globosa, and 4 µg/mL for S. schenckii. Itraconazole ECVs were 4 µg/mL for S. brasiliensis and S. schenckii. Posaconazole ECVs were 4 µg/mL for all three species (tentative for S. globosa), while the terbinafine ECV for S. brasiliensis was 0.12 µg/mL. Overall, this study establishes validated ECVs for key antifungals against Sporothrix species and identifies a low prevalence of non-wild-type (NWT) isolates (<10% except for S. schenckii and posaconazole), supporting ongoing antifungal resistance monitoring.